BioSpace News Archive

The Centers for Medicare & Medicaid Services announced that effective July 26, Medicare will provide coverage of the inFlow device as an alternative to intermittent catheterization for beneficiaries with Permanent Urinary Retention due to Impaired Detrusor Contractility.

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce that it has further accelerated its path to commercialization following continued scale-up development success and the addition of multiple new cannabinoids for production. Willow is a Canadian biotechnology comp

Final analysis of the Phase 1/2 clinical study to be presented as a late-breaking virtual presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGI) on July 1, 2020

Ascentage Pharma announced that the Phase II clinical study of the company’s novel inhibitor of apoptosis proteins antagonist APG-1387 in combination with entecavir for the treatment of patients with CHB has dosed its first patient in China.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the healthcare investment bank Chardan has initiated analyst coverage of Sensorion.

Combines Best-in-Class Bone Repair with Intraoperative Ease-of-Use for Spine and Trauma Bone Grafting Applications

Mandy Hale, DNP, MSN, MBA, RN, CNN, promoted to new clinical leadership role after 19 years of serving dialysis patients with DaVita

Merck, known as MSD outside the United States and Canada, yesterday priced a $4.5 billion public offering of four series of senior unsecured notes.

Foundation Medicine, Inc., announced that the US FDA approved FoundationOne®CDx as a companion diagnostic for KEYTRUDA®, Merck’s anti-PD-1 therapy, which was also approved under accelerated approval for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high [≥10 mutations/megabase ] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

Company aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and autoimmune disorders